Begin typing your search...

Glenmark's IPO subscribed 2.78 times on first day

The initial public offer of Glenmark Life Sciences Limited was subscribed 2.78 times on the first day of subscription on Tuesday.

image for illustrative purpose

Glenmark recalls generic hypertension drug in US
X

27 July 2021 10:04 PM IST

New Delhi: The initial public offer of Glenmark Life Sciences Limited was subscribed 2.78 times on the first day of subscription on Tuesday. The IPO received bids for 4,17,79,260 shares against 1,50,18,279 shares on offer, as per data available with the NSE. The non-institutional investors' category was subscribed 86 per cent and those for retail individual investors(RIIs) 5.17 times. The initial public offer comprises a fresh issue of up to Rs 1,060 crore and an offer for sale of up to 63 lakh equity shares. The price range for the offer, which will conclude on Thursday, has been fixed at Rs 695-720 per share.

Glenmark Life Sciences on Monday raised Rs 454 crore from anchor investors. At the upper end of the price band, the IPO will fetch Rs 1,513.6 crore. Proceeds from the fresh issue will be used towards the payment of outstanding purchase consideration to the promoter for the spin-off of the API business and funding the capital expenditure requirements. Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals, is a leading developer and manufacturer of select high-value, non-commoditised active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management, and diabetes.

Glenmark Life Sciences Limited IPO 
Next Story
Share it